{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:55:45Z","timestamp":1790708145118,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.jval.2012.11.004","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T01:48:42Z","timestamp":1359510522000},"page":"297-304","source":"Crossref","is-referenced-by-count":71,"title":["Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States"],"prefix":"10.1016","volume":"16","author":[{"given":"Paul M.","family":"Stranges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis D.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2012.11.004_bib1","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","article-title":"Clostridium difficile--more difficult than ever","volume":"359","author":"Kelly","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.11.004_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3201\/eid1205.051064","article-title":"Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003","volume":"12","author":"McDonald","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib3","unstructured":"Lucado J., Gould C., Elixhauser A. Statistical Brief #124:\u00a0Healthcare Cost and Utilization Project (HCUP) Clostridium difficile infections (CDI) in hospital stays, 2009.\u00a0 Available from: http:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb124.pdf. [Accessed February 24, 2012]."},{"key":"10.1016\/j.jval.2012.11.004_bib4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3201\/eid1406.071447","article-title":"Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005","volume":"14","author":"Zilberberg","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(05)70215-2","article-title":"Treatment of Clostridium difficile-associated disease: old therapies and new strategies","volume":"5","author":"Aslam","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib6","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1053\/j.gastro.2008.12.070","article-title":"Treatment ofClostridium difficile-associated disease","volume":"136","author":"Leffler","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.11.004_bib7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/338260","article-title":"Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile","volume":"34","author":"Kyne","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/522676","article-title":"The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences","volume":"28","author":"O\u2019Brien","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jval.2012.11.004_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/sur.2006.062","article-title":"The burden of Clostridium difficile in surgical patients in the United States","volume":"8","author":"Zerey","year":"2007","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.jval.2012.11.004_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.11.004_bib11","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/AAC.48.6.2280-2282.2004","article-title":"In vitro activity of OPT-80 against Clostridium difficile","volume":"48","author":"Ackermann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jval.2012.11.004_bib12","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","article-title":"A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","author":"Tannock","year":"2010","journal-title":"Microbiology"},{"key":"10.1016\/j.jval.2012.11.004_bib13","unstructured":"AmerisourceBergen Corporation.\u00a0BlueBook AWP. Available from: https:\/\/coe.amerisourcebergen.com\/coe\/Interlinx\/pgStartHere. [Accessed\u00a0March 6, 2012]."},{"key":"10.1016\/j.jval.2012.11.004_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1345\/aph.1Q481","article-title":"Fidaxomicin for the treatment of Clostridium difficile infections","volume":"46","author":"Whitman","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jval.2012.11.004_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/cid\/cir830","article-title":"Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficileinfection","volume":"54","author":"Venugopal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1469-0691.2011.03571.x","article-title":"The economic burden of Clostridium difficile","volume":"18","author":"McGlone","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jval.2012.11.004_bib17","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2010.05.062","article-title":"The potential value of Clostridium difficile vaccine: an economic computer simulation model","volume":"28","author":"Lee","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2012.11.004_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jval.2012.11.004_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00000658-200203000-00008","article-title":"Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications","volume":"235","author":"Dallal","year":"2002","journal-title":"Ann Surg"},{"key":"10.1016\/j.jval.2012.11.004_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archsurg.2007.46","article-title":"Predictors of mortality after colectomy for fulminant Clostridium difficile colitis","volume":"143","author":"Byrn","year":"2008","journal-title":"Arch Surg"},{"key":"10.1016\/j.jval.2012.11.004_bib22","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2012.11.004_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/cid\/cir668","article-title":"Risk factors associated with complications and mortality in patients with Clostridium difficile infection","volume":"53","author":"Morrison","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib24","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s10350-004-0672-2","article-title":"Outcome after colectomy for Clostridium difficile colitis","volume":"47","author":"Longo","year":"2004","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jval.2012.11.004_bib25","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1111\/j.1572-0241.2008.02198.x","article-title":"Clinical review of the management of fulminant Clostridium difficile infection","volume":"103","author":"Jaber","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2012.11.004_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1463-1318.2005.00876.x","article-title":"The outcome of surgery in fulminant Clostridium difficile colitis","volume":"8","author":"Koss","year":"2006","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COC.0b013e31817c6a4d","article-title":"A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer","volume":"32","author":"Tumeh","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jval.2012.11.004_bib28","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell\u2019Italia Meridionale","volume":"23","author":"Colucci","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2012.11.004_bib29","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2012.11.004_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10198-009-0199-5","article-title":"Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis","volume":"11","author":"Punekar","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2012.11.004_bib31","unstructured":"Bureau of Labor Statistics.\u00a0Consumer Price Index-all urban consumers. Available from: http:\/\/data.bls.gov\/cgi-bin\/surveymost. [Accessed March 4, 2012]."},{"key":"10.1016\/j.jval.2012.11.004_bib32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/17453671003587119","article-title":"Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures","volume":"81","author":"Slobogean","year":"2010","journal-title":"Acta Orthop"},{"key":"10.1016\/j.jval.2012.11.004_bib33","unstructured":"Murray CJL, Lopez AD. Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press, 1996."},{"key":"10.1016\/j.jval.2012.11.004_bib34","unstructured":"World Health Organization.\u00a0Global Health Observatory Data Repository Life Tables. Available from: http:\/\/apps.who.int\/ghodata\/. [Accessed March 4, 2012]."},{"key":"10.1016\/j.jval.2012.11.004_bib35","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1046\/j.1365-2036.2003.01545.x","article-title":"Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications","volume":"17","author":"Ladabaum","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jval.2012.11.004_bib36","first-page":"561","article-title":"How preliminary data affect people\u2019s stated willingness to enter a hypothetical randomized controlled trial","volume":"45","author":"Ubel","year":"1997","journal-title":"J Investig Med"},{"key":"10.1016\/j.jval.2012.11.004_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","article-title":"Willingness to pay for a quality-adjusted life year: in search of a standard","volume":"20","author":"Hirth","year":"2000","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2012.11.004_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1524-4733.2008.00401.x","article-title":"An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.11.004_bib39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.7326\/0003-4819-155-12-201112200-00007","article-title":"Comparative effectiveness of Clostridium difficile treatments: a systematic review","volume":"155","author":"Drekonja","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2012.11.004_bib41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib42","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1503\/cmaj.050978","article-title":"Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec","volume":"173","author":"Pepin","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.jval.2012.11.004_bib43","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa051639","article-title":"A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality","volume":"353","author":"Loo","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.11.004_bib44","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1128\/JCM.05053-11","article-title":"Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes","volume":"49","author":"Sirard","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jval.2012.11.004_bib45","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cgh.2009.05.018","article-title":"Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting","volume":"7","author":"Cloud","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jval.2012.11.004_bib46","doi-asserted-by":"crossref","first-page":"e1812","DOI":"10.1371\/journal.pone.0001812","article-title":"Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study","volume":"3","author":"Morgan","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2012.11.004_bib47","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1086\/653012","article-title":"Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom","volume":"50","author":"Wilson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib48","unstructured":"Health Resources and Services Administration. 340B Drug Pricing and Pharmacy Affairs. Available from http:\/\/www.hrsa.gov\/opa\/index.html [Accessed January 1, 2013]."},{"key":"10.1016\/j.jval.2012.11.004_bib49","unstructured":"Jump RNM, Pultz M, Donskey C. Effect of antibiotic used for treatment of Clostridium difficile infection on intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice [abstract]. Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2011."},{"key":"10.1016\/j.jval.2012.11.004_bib50","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1086\/323758","article-title":"Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop","volume":"33","author":"Howard","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib51","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/clinids\/23.6.1234","article-title":"Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality","volume":"23","author":"Edmond","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib52","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/infdis\/172.4.993","article-title":"Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections","volume":"172","author":"Shay","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2012.11.004_bib53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3201\/eid0702.010228","article-title":"Economic impact of antimicrobial resistance","volume":"7","author":"McGowan","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.jval.2012.11.004_bib54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1473-3099(12)70013-0","article-title":"Progress with a difficult infection","volume":"12","author":"Wilcox","year":"2012","journal-title":"Lancet Infect Dis"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512042441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512042441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T03:32:10Z","timestamp":1539919930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301512042441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1098301512042441"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2012.11.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}